Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200337400> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4200337400 endingPage "vi61" @default.
- W4200337400 startingPage "vi61" @default.
- W4200337400 abstract "Abstract BACKGROUND Low-grade gliomas (LGGs) are common benign brain tumors that arise from glial cells of the brain. The complex and variable backgrounds of LGGs cause difficulties in assigning therapies. In this report, we compile findings relating to LGG genetics and treatment options in order to create a coherent summary for referential use. METHODS We compiled 70 articles from the past ten years that cover a broad range of topics pertaining to LGGs, including molecular, genetic, epigenetic, morphological, and other diagnostic factors, as well as prognosis and treatment options. RESULTS In order to provide proper treatment, the molecular basis and histology of the tumor must be addressed. The 1p/19q co-deletion indicator has been considered the gold standard of glioma diagnosis, but oft-sighted mutations in the IDH1 and IDH2 genes have given rise to three subgroups of 1p/19q co-deleted tumors, each associated with specific patterns of nervous cells. Other molecular markers and microRNA expression patterns have been studied for possible diagnostic and prognostic methods. Microsurgical resection is the singular treatment with highest overall survival (OS) and quality of life (QOL). Total gross resection is optimal, with patients having a 5-year OS of 100% with 90% tumor resection. Low doses of radiation are as effective as high doses and are better tolerated (with less cognitive deficits). Chemotherapy, specifically temozolomide, offers a favorable toxicity profile and QOL; additionally, seizure reduction is an early and consistent prognostic marker for survival after treatment with temozolomide. CONCLUSIONS The “wait and see” approach for treatment is no longer the standard for LGGs. Immediate treatment after diagnosis is recommended. Gross total resection (if achievable) is the most favorable treatment, with the highest OS and QOL. The use of temozolomide and radiotherapy is recommended. Histological background and genetic markers are vital for determining a treatment plan." @default.
- W4200337400 created "2021-12-31" @default.
- W4200337400 creator A5002097143 @default.
- W4200337400 creator A5056108766 @default.
- W4200337400 creator A5056327142 @default.
- W4200337400 creator A5056541280 @default.
- W4200337400 date "2021-11-02" @default.
- W4200337400 modified "2023-09-25" @default.
- W4200337400 title "CTNI-10. ADVANCES IN MANAGEMENT OF LOW-GRADE GLIOMAS" @default.
- W4200337400 doi "https://doi.org/10.1093/neuonc/noab196.235" @default.
- W4200337400 hasPublicationYear "2021" @default.
- W4200337400 type Work @default.
- W4200337400 citedByCount "0" @default.
- W4200337400 crossrefType "journal-article" @default.
- W4200337400 hasAuthorship W4200337400A5002097143 @default.
- W4200337400 hasAuthorship W4200337400A5056108766 @default.
- W4200337400 hasAuthorship W4200337400A5056327142 @default.
- W4200337400 hasAuthorship W4200337400A5056541280 @default.
- W4200337400 hasBestOaLocation W42003374001 @default.
- W4200337400 hasConcept C104317684 @default.
- W4200337400 hasConcept C126322002 @default.
- W4200337400 hasConcept C127848430 @default.
- W4200337400 hasConcept C142724271 @default.
- W4200337400 hasConcept C143998085 @default.
- W4200337400 hasConcept C2776059313 @default.
- W4200337400 hasConcept C2777389519 @default.
- W4200337400 hasConcept C2777931997 @default.
- W4200337400 hasConcept C2778227246 @default.
- W4200337400 hasConcept C2778880634 @default.
- W4200337400 hasConcept C2779130545 @default.
- W4200337400 hasConcept C501734568 @default.
- W4200337400 hasConcept C502942594 @default.
- W4200337400 hasConcept C509974204 @default.
- W4200337400 hasConcept C55493867 @default.
- W4200337400 hasConcept C71924100 @default.
- W4200337400 hasConcept C86803240 @default.
- W4200337400 hasConceptScore W4200337400C104317684 @default.
- W4200337400 hasConceptScore W4200337400C126322002 @default.
- W4200337400 hasConceptScore W4200337400C127848430 @default.
- W4200337400 hasConceptScore W4200337400C142724271 @default.
- W4200337400 hasConceptScore W4200337400C143998085 @default.
- W4200337400 hasConceptScore W4200337400C2776059313 @default.
- W4200337400 hasConceptScore W4200337400C2777389519 @default.
- W4200337400 hasConceptScore W4200337400C2777931997 @default.
- W4200337400 hasConceptScore W4200337400C2778227246 @default.
- W4200337400 hasConceptScore W4200337400C2778880634 @default.
- W4200337400 hasConceptScore W4200337400C2779130545 @default.
- W4200337400 hasConceptScore W4200337400C501734568 @default.
- W4200337400 hasConceptScore W4200337400C502942594 @default.
- W4200337400 hasConceptScore W4200337400C509974204 @default.
- W4200337400 hasConceptScore W4200337400C55493867 @default.
- W4200337400 hasConceptScore W4200337400C71924100 @default.
- W4200337400 hasConceptScore W4200337400C86803240 @default.
- W4200337400 hasIssue "Supplement_6" @default.
- W4200337400 hasLocation W42003374001 @default.
- W4200337400 hasOpenAccess W4200337400 @default.
- W4200337400 hasPrimaryLocation W42003374001 @default.
- W4200337400 hasRelatedWork W165245056 @default.
- W4200337400 hasRelatedWork W2104436150 @default.
- W4200337400 hasRelatedWork W2128680685 @default.
- W4200337400 hasRelatedWork W2149409455 @default.
- W4200337400 hasRelatedWork W2539857427 @default.
- W4200337400 hasRelatedWork W2808624194 @default.
- W4200337400 hasRelatedWork W3013369088 @default.
- W4200337400 hasRelatedWork W3205069009 @default.
- W4200337400 hasRelatedWork W3216911427 @default.
- W4200337400 hasRelatedWork W619371956 @default.
- W4200337400 hasVolume "23" @default.
- W4200337400 isParatext "false" @default.
- W4200337400 isRetracted "false" @default.
- W4200337400 workType "article" @default.